Portuguese pharma braced for tough 2011
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry in Portugal is bracing itself for a tough 2011, which will see the effects of multiple price cuts, changes to the reference pricing system, greater patient co-payments and spiralling government debts. Worth around €3.5 billion in 2010, the market looks set to contract by between 7% and 10% in 2011, says Luis Frade, general manager of the consultancy firm Cegedim Portugal.